Added Effect of 1% Topical Alendronate in Intra-bony and Inter-radicular Defects As Part of Step II Periodontal Therapy: a Systematic Review with Meta-analysis and Trial Sequential Analysis

Overview

Journal BMC Oral Health

Publisher Biomed Central

Specialty Dentistry

Date 2022 Jan 22

PMID 35062940

Authors

Claudia Arena

Vito Carlo Alberto Caponio

Khrystyna Zhurakivska

Lucio Lo Russo

Lorenzo Lo Muzio

Giuseppe Troiano

Affiliations

Soon will be listed here.

Abstract

Background: This systematic review and meta-analysis aimed to investigate the role of alendronate combined with step 2 of periodontal therapy in reducing probing pocket depth, improving clinical attachment level, and reducing bone defect depth in intra-bony and inter-radicular defects.

Methods: RCTs with more than 6 months follow-up were included in this study. Risk of bias assessment was performed using the Cochrane collaboration tool. In addition, meta-analysis and trial sequential analysis were used to aggregate the available evidence.

Results: Seven studies met the inclusion criteria and were included in the systematic review. Topical application of alendronate during second step of periodontal therapy significantly improved PD and CAL.

Conclusion: Local application of alendronate may confer a beneficial effect when applied during step II of periodontal therapy even if long term studies are needed to confirm these results.

Clinical Relevance: Considering the emerging role of host-inflammatory response in treatment of periodontitis and the antiresorptive and osteostimulative properties of bisphosphonates, several studies are focusing on the role of alendronate as an addition to non-surgical periodontal therapy.

Citing Articles

Zoledronic acid affects the process of infecting oral mucosal epithelial barrier: An and study.

Sun H, Li P, Kong Q, Deng F, Yu X Front Cell Infect Microbiol. 2023; 13:1104826.

PMID: 37056703 PMC: 10086244. DOI: 10.3389/fcimb.2023.1104826.

Local drug delivery in the treatment of furcation defects in periodontitis: a systematic review.

Chatzopoulos G, Koidou V, Tsalikis L Clin Oral Investig. 2023; 27(3):955-970.

PMID: 36729235 PMC: 9985576. DOI: 10.1007/s00784-023-04871-0.

Roles of osteoclasts in alveolar bone remodeling.

Omi M, Mishina Y Genesis. 2022; 60(8-9):e23490.

PMID: 35757898 PMC: 9786271. DOI: 10.1002/dvg.23490.

References

Yen C, Damoulis P, Stark P, Hibberd P, Singh M, Papas A . The effect of a selective cyclooxygenase-2 inhibitor (celecoxib) on chronic periodontitis. J Periodontol. 2008; 79(1):104-13. DOI: 10.1902/jop.2008.070271. View

Reddy G, Kumar T, Veena . Formulation and evaluation of Alendronate Sodium gel for the treatment of bone resorptive lesions in Periodontitis. Drug Deliv. 2005; 12(4):217-22. DOI: 10.1080/10717540590952663. View

Johnson G, Hill M . Cigarette smoking and the periodontal patient. J Periodontol. 2004; 75(2):196-209. DOI: 10.1902/jop.2004.75.2.196. View

Elbourne D, Altman D, Higgins J, Curtin F, Worthington H, Vail A . Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol. 2002; 31(1):140-9. DOI: 10.1093/ije/31.1.140. View

Ipshita S, Kurian I, Dileep P, Kumar S, Singh P, Pradeep A . One percent alendronate and aloe vera gel local host modulating agents in chronic periodontitis patients with class II furcation defects: A randomized, controlled clinical trial. J Investig Clin Dent. 2018; 9(3):e12334. DOI: 10.1111/jicd.12334. View

Salvi G, Lang N . Host response modulation in the management of periodontal diseases. J Clin Periodontol. 2005; 32 Suppl 6:108-29. DOI: 10.1111/j.1600-051X.2005.00785.x. View

Akram Z, Abduljabbar T, Kellesarian S, Abu Hassan M, Javed F, Vohra F . Efficacy of bisphosphonate as an adjunct to nonsurgical periodontal therapy in the management of periodontal disease: a systematic review. Br J Clin Pharmacol. 2016; 83(3):444-454. PMC: 5306480. DOI: 10.1111/bcp.13147. View

Sanz M, Herrera D, Kebschull M, Chapple I, Jepsen S, Beglundh T . Treatment of stage I-III periodontitis-The EFP S3 level clinical practice guideline. J Clin Periodontol. 2020; 47 Suppl 22:4-60. PMC: 7891343. DOI: 10.1111/jcpe.13290. View

Lesaffre E, Philstrom B, Needleman I, Worthington H . The design and analysis of split-mouth studies: what statisticians and clinicians should know. Stat Med. 2009; 28(28):3470-82. DOI: 10.1002/sim.3634. View

10.

Haffajee A, Socransky S . Microbial etiological agents of destructive periodontal diseases. Periodontol 2000. 1994; 5:78-111. DOI: 10.1111/j.1600-0757.1994.tb00020.x. View

11.

Needleman I, Pandya N, Smith S, Foyle D . The role of antibiotics in the treatment of periodontitis (Part 2--Controlled drug delivery). Eur J Prosthodont Restor Dent. 1995; 3(3):111-7. View

12.

Goziotis A, Sukhu B, Torontali M, Dowhaniuk M, Tenenbaum H . Effects of bisphosphonates APD and HEBP on bone metabolism in vitro. Bone. 1995; 16(4 Suppl):317S-327S. DOI: 10.1016/8756-3282(95)00044-e. View

13.

Chavassieux P, Arlot M, Reda C, Wei L, Yates A, Meunier P . Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 1997; 100(6):1475-80. PMC: 508326. DOI: 10.1172/JCI119668. View

14.

Feng H, Bernardo C, Sonoda L, Hayashi F, Romito G, de Lima L . Subgingival ultrasonic instrumentation of residual pockets irrigated with essential oils: a randomized controlled trial. J Clin Periodontol. 2011; 38(7):637-43. DOI: 10.1111/j.1600-051X.2011.01725.x. View

15.

Liberman U, Weiss S, Broll J, Minne H, Quan H, Bell N . Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995; 333(22):1437-43. DOI: 10.1056/NEJM199511303332201. View

16.

Hujoel P, DeRouen T . Validity issues in split-mouth trials. J Clin Periodontol. 1992; 19(9 Pt 1):625-7. DOI: 10.1111/j.1600-051x.1992.tb01709.x. View

17.

Dutra B, Dutra Oliveira A, Dutra Oliveira P, Manzi F, Cortelli S, Cota L . Effect of 1% sodium alendronate in the non-surgical treatment of periodontal intraosseous defects: a 6-month clinical trial. J Appl Oral Sci. 2017; 25(3):310-317. PMC: 5482254. DOI: 10.1590/1678-7757-2016-0252. View

18.

Pradeep A, Kanoriya D, Singhal S, Garg V, Manohar B, Chatterjee A . Comparative evaluation of subgingivally delivered 1% alendronate versus 1.2% atorvastatin gel in treatment of chronic periodontitis: a randomized placebo-controlled clinical trial. J Investig Clin Dent. 2016; 8(3). DOI: 10.1111/jicd.12215. View

19.

Brunsvold M, Chaves E, Kornman K, Aufdemorte T, Wood R . Effects of a bisphosphonate on experimental periodontitis in monkeys. J Periodontol. 1992; 63(10):825-30. DOI: 10.1902/jop.1992.63.10.825. View

20.

Adami S, Bhalla A, Dorizzi R, Montesanti F, Rosini S, Salvagno G . The acute-phase response after bisphosphonate administration. Calcif Tissue Int. 1987; 41(6):326-31. DOI: 10.1007/BF02556671. View